Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients

Sadat City University

Status and phase: Withdrawn; Phase 2; Phase 1

Conditions: COVID

Treatments: Drug: Pentoxifylline; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04433988

RC-6-2020

Details and patient eligibility

About

With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects on immune modulation, inflammation and oxidative stress. As the main regulator of cAMP metabolism, posphodiesterase-4 plays a key role in proinflammatory and immune cells. Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory cytokines such as TNF-a, IL-1 and IL-6. Given its unique impacts on immune modulation, homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ failure, pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for COVID-19 patients.

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Positive COVID-19 test
• Age >/= 18 y.o.

Exclusion criteria

• Allergic reaction to Pentoxifylline
• Ongoing anticoagulation
• History of GI bleeding
• History of Seizures
• Cardiac or other vascular stents
• History of severe renal disease
• History of intracranial hemorrhage.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

0 participants in 2 patient groups, including a placebo group

Control group

Placebo Comparator group

Description:

100 patients will receive standard treatment plus placebo

Treatment:

Drug: Placebo

Pentoxifylline group

Experimental group

Description:

100 patients will receive standard treatment plus pentoxifylline 1200 mg/day

Treatment:

Drug: Pentoxifylline